SynteractHCR Announces Webinar Series For Clinical Research And Biopharma Professionals

Industry experts will provide insights into companion diagnostics, adaptive trial design and EU clinical trial regulation

SAN DIEGO--(BUSINESS WIRE)--SynteractHCR, a full-service, international contract research organization (CRO), will host a series of educational webinars focused on new requirements, considerations and intricacies in the clinical trial and drug development process. Led by SynteractHCR’s senior experts, each webinar is accessible online to anyone interested and free of charge to attendees.

The first webinar, “Pitfalls in Companion Diagnostics,” will take place on Thursday, April 30 from 11 a.m. to 12 p.m. EDT. The webinar will be presented by SynteractHCR’s Chief Medical Advisor, Dr. Stephan de la Motte, and will demonstrate the conditional nature of diagnostics, particularly on companion diagnostics and the role it plays in drug discovery and development. By examining a tree of conditional probabilities, the presentation explores the various dependencies, intricacies and pitfalls in a world where nothing is 100 percent certain, and how it is possible to draw the right conclusions in the face of uncertainty. Dr. de la Motte was named one of the PharmaVOICE 100 Most Inspiring People in Life Sciences last year.

The second webinar, “Adaptive Trial Design” will be held on Thursday, June 4 from 1 to 2 p.m. EDT. Greg Wei, Ph.D., director of biostatistics, will provide insight into adaptive trials consulting and the role it plays in managing efficient global clinical trials. Wei has direct regulatory experience with the FDA and EMA, and has presented to both agencies on special protocol assessment and adaptive trial design, both of which are crucial areas for pharma and biotech companies as they are pressured to increase trial efficiency and reduce study costs.

The final webinar of the series, “EU Clinical Trial Regulation,” will take place on Thursday, July 23 from 11 a.m. to 12 p.m. EDT. Dr. Martine Dehlinger-Kremer, vice president, global medical and regulatory affairs, will outline the importance of new administrative provisions governing clinical trials in the European Union. For 19 years, she has served as a vice president of International and Global Regulatory Affairs and Global Medical Affairs at various CROs.

About SynteractHCR

SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and in more than 60 countries, offering expertise across multiple therapeutic areas and with notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy and ICD+ approach, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data so clients get to decision points faster.